Mangoceuticals, Inc. (NASDAQ: MGRX) announced the closing of a registered direct offering on October 9, 2026. The transaction involved the issuance of 657,000 shares of common stock and accompanying warrants to purchase an additional 657,000 shares of common stock. The offering was priced at $0.75 per unit, with each unit consisting of one share and one warrant. This price represents an approximately 74% premium to the company's recent closing share price of $0.43.
The company expects to receive gross proceeds of approximately $492,750 from the sale of the shares and warrants. The shares and warrants are immediately separable but must be purchased together in the offering. Each warrant is exercisable immediately upon issuance at a price of $1.00 per share and will expire five years from the date of issuance. Holders may also exercise the warrants on a cashless basis, receiving shares equal to the number of shares being multiplied by 1.08 without payment of the exercise price.
The securities were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-288039) that was declared effective by the SEC on June 24, 2025. The company stated that it intends to use the net proceeds from the offering for working capital and general corporate purposes. The company did not engage a placement agent, underwriter, or financial advisor for this transaction.
The press release accompanying the closing notes that the offering follows a separate strategic investment commitment of $2.5 million made to the company's subsidiary, MangoRx IP Holdings, LLC. That subsidiary has received $1.75 million of the committed capital, with the remaining $750,000 due by November 28, 2026. The subsidiary financing was intended to support the commercialization of intellectual property without directly diluting the parent company's common stock.
